AR108461A1 - Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer - Google Patents
Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncerInfo
- Publication number
- AR108461A1 AR108461A1 ARP170101261A ARP170101261A AR108461A1 AR 108461 A1 AR108461 A1 AR 108461A1 AR P170101261 A ARP170101261 A AR P170101261A AR P170101261 A ARP170101261 A AR P170101261A AR 108461 A1 AR108461 A1 AR 108461A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- pharmaceutically acceptable
- acceptable salts
- formula
- quinolin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical group C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta memoria descriptiva se refiere generalmente a los compuestos de la fórmula (1), y sus sales farmacéuticamente aceptables, en la cual R¹ es 4-flúor piperidin-1-il o 3-flúor pirrolidin-1-il y R² es metilo o hidro; el uso de los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables para tratar o prevenir una enfermedad mediada por ATM, incluyendo cáncer; composiciones farmacéuticas que comprenden compuestos sustituidos imidazo[4,5-c]quinolin-2-ona o sus sales farmacéuticamente aceptables; estuches que comprenden los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables; métodos para la fabricación de los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables; e intermedios útiles en tal fabricación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608227.3A GB201608227D0 (en) | 2016-05-11 | 2016-05-11 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108461A1 true AR108461A1 (es) | 2018-08-22 |
Family
ID=56297492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101261A AR108461A1 (es) | 2016-05-11 | 2017-05-11 | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR108461A1 (es) |
| GB (1) | GB201608227D0 (es) |
| TW (1) | TW201805284A (es) |
| WO (1) | WO2017194632A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| CN112752758B (zh) * | 2018-09-14 | 2023-05-23 | 苏州赞荣医药科技有限公司 | 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 |
| JP6997358B2 (ja) * | 2018-09-30 | 2022-01-17 | メッドシャイン ディスカバリー インコーポレイテッド | キノリノピロリジン－２－オン系誘導化合物及びその使用 |
| WO2021098734A1 (zh) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN118434736A (zh) * | 2022-01-26 | 2024-08-02 | 正大天晴药业集团股份有限公司 | 含有肼基的化合物 |
| CN115778962B (zh) * | 2022-11-28 | 2024-09-17 | 中国医学科学院肿瘤医院 | 治疗男性食管癌患者的药物及其相关应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
-
2016
- 2016-05-11 GB GBGB1608227.3A patent/GB201608227D0/en not_active Ceased
-
2017
- 2017-05-10 WO PCT/EP2017/061229 patent/WO2017194632A1/en not_active Ceased
- 2017-05-10 TW TW106115396A patent/TW201805284A/zh unknown
- 2017-05-11 AR ARP170101261A patent/AR108461A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201608227D0 (en) | 2016-06-22 |
| TW201805284A (zh) | 2018-02-16 |
| WO2017194632A1 (en) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
| CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |